To see all protocols that comply with the WHO Essential Medicine List 

This protocol has been superseded because it is not commonly used in clinical practice

 Ranitidine recall:

The TGA has suspended the registration of all ranitidine medicines. Further information is available from the TGA safety alert. Ranitidine is included as a default premedication in eviQ protocols and alternative approaches should be considered based on assessment of individual patients, institutional policy and availability of alternative drugs. Refer to BOPA Guidance on use of H2 antagonists for hypersensitivity for more information.

This protocol is based on limited evidence; please refer to the evidence section of this protocol for more information.

Check for clinical trials in this patient group. Link to Australian Clinical Trials website

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Last reviewed:
Review due:
Superseded:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/1629

29 Sep 2020